Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.

BMC cancer - 8 Sept 2017

Philip Charles-André, Laskov Ido, Beauchamp Marie-Claude, Marques Maud, Amin Oreekha, Bitharas Joanna, Kessous Roy, Kogan Liron, Baloch Tahira, Gotlieb Walter H, Yasmeen Amber

Abstract excerpt

BACKGROUND: Phosphatase and Tensin homolog (PTEN) is a tumor suppressor gene. Loss of its function is the most frequent genetic alteration in endometrioid endometrial cancers (70-80%) and high grade tumors (90%). We assessed the sensitivity of endometrial cancer cell lines to PARP inhibitors (olaparib and BMN-673) and a PI3K inhibitor (BKM-120), alone or in combination, in the context of their PTEN mutation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Endometrial Neoplasms
Share to Phosphoinositide-3 Kinase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phthalazines

Share to Piperazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to PTEN Phosphohydrolase

Share to Rad51 Recombinase

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 28886696
DOI: 10.1186/s12885-017-3639-0
PMCID: PMC5591502

Genes

PTEN
RAD51

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.PMID 28886696Read ↗

PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapySemantic proximity Read ↗

PARP Inhibitors in Endometrial Cancer: Current Status and PerspectivesSemantic proximity Read ↗

Phosphatase and Tensin Homolog Is a Potential Target for Ovarian Cancer Sensitization to Cytotoxic Agents.Semantic proximity Read ↗

Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer.Semantic proximity Read ↗

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.Semantic proximity Read ↗

Research Progress of PARP Inhibitor Monotherapy and Combination Therapy for Endometrial CancerSemantic proximity Read ↗

Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancerSemantic proximity Read ↗

PTEN-negative endometrial cancer cells protect their genome through enhanced DDB2 expression associated with augmented nucleotide excision repairSemantic proximity Read ↗

RAD51-Mediated DNA Homologous Recombination Is Independent of PTEN Mutational StatusSemantic proximity Read ↗

Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer.Semantic proximity Read ↗

PTEN Loss Enhances Error-Prone DSB Processing and Tumor Cell Radiosensitivity by Suppressing RAD51 Expression and Homologous RecombinationSemantic proximity Read ↗

Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.